TY  - JOUR
AU  - Vogelgsang, Jonathan
AU  - Hansen, Niels
AU  - Stark, Melina
AU  - Wagner, Michael
AU  - Klafki, Hans
AU  - Morgado, Barbara Marcos
AU  - Jahn-Brodmann, Anke
AU  - Schott, Björn
AU  - Esselmann, Hermann
AU  - Bauer, Chris
AU  - Schuchhardt, Johannes
AU  - Kleineidam, Luca
AU  - Wolfsgruber, Steffen
AU  - Peters, Oliver
AU  - Schneider, Luisa-Sophie
AU  - Wang, Xiao
AU  - Menne, Felix
AU  - Priller, Josef
AU  - Spruth, Eike Jakob
AU  - Altenstein, Slawek
AU  - Lohse, Andrea
AU  - Schneider, Anja
AU  - Fliessbach, Klaus
AU  - Vogt, Ina
AU  - Bartels, Claudia
AU  - Jessen, Frank
AU  - Rostamzadeh, Ayda
AU  - Duezel, Emrah
AU  - Glanz, Wenzel
AU  - Incesoy, Enise
AU  - Butryn, Michaela
AU  - Buerger, Katharina
AU  - Janowitz, Daniel
AU  - Ewers, Michael
AU  - Perneczky, Robert
AU  - Rauchmann, Boris Stephan
AU  - Guersel, Selim
AU  - Teipel, Stefan
AU  - Kilimann, Ingo
AU  - Goerss, Doreen
AU  - Laske, Christoph
AU  - Munk, Matthias
AU  - Sanzenbacher, Carolin
AU  - Spottke, Annika
AU  - Roy-Kluth, Nina
AU  - Heneka, Michael
AU  - Brosseron, Frederic
AU  - Ramirez, Alfredo
AU  - Schmid, Matthias
AU  - Wiltfang, Jens
TI  - Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.
JO  - Alzheimer's and dementia
VL  - 20
IS  - 8
SN  - 1552-5260
CY  - Hoboken, NJ
PB  - Wiley
M1  - DZNE-2024-01078
SP  - 5132 - 5142
PY  - 2024
AB  - Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for predicting cognitive decline.We measured levels of amyloid beta (Aβ)X-40 and AβX-42 in immunoprecipitated eluates from the DELCODE cohort. Receiver-operating characteristic (ROC) curves, regression analyses, and Cox proportional hazard regression models were constructed to predict AP by Aβ42/40 classification in cerebrospinal fluid (CSF) and conversion to mild cognitive impairment (MCI) or dementia.We detected a significant correlation between AßX-42/X-40 in plasma and CSF (r = 0.473). Mixed-modeling analysis revealed a substantial prediction of AßX-42/X-40 with an area under the curve (AUC) of 0.81 for AP (sensitivity: 0.79, specificity: 0.74, positive predictive value [PPV]: 0.71, negative predictive value [NPV]: 0.81). In addition, lower AβX-42/X-40 ratios were associated with negative PACC5 slopes, suggesting cognitive decline.Our results suggest that assessing the plasma AβX-42/X-40 ratio via our semiautomated IP-IA is a promising biomarker when examining patients with early or preclinical AD.New plasma Aβ42/Aβ40 measurement using immunoprecipitation-immunoassay Plasma Aβ42/Aβ40 associated with longitudinal cognitive decline Promising biomarker to detect subjective cognitive decline at-risk for brain amyloid positivity.
KW  - Humans
KW  - Amyloid beta-Peptides: blood
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Alzheimer Disease: blood
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: cerebrospinal fluid
KW  - Cognitive Dysfunction: blood
KW  - Cognitive Dysfunction: cerebrospinal fluid
KW  - Cognitive Dysfunction: diagnosis
KW  - Male
KW  - Female
KW  - Aged
KW  - Biomarkers: blood
KW  - Biomarkers: cerebrospinal fluid
KW  - Peptide Fragments: blood
KW  - Peptide Fragments: cerebrospinal fluid
KW  - Middle Aged
KW  - ROC Curve
KW  - Immunoprecipitation
KW  - Disease Progression
KW  - Alzheimer's disease (Other)
KW  - MCI (Other)
KW  - amyloid beta (Other)
KW  - biomarker (Other)
KW  - dementia (Other)
KW  - plasma (Other)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Peptide Fragments (NLM Chemicals)
KW  - amyloid beta-protein (1-42) (NLM Chemicals)
KW  - amyloid beta-protein (1-40) (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC11350048
C6  - pmid:38940303
DO  - DOI:10.1002/alz.13909
UR  - https://pub.dzne.de/record/271866
ER  -